Print this page

First-in-Human Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of the BTK Degrader, ABBV-101, in Participants with B-cell Malignancies

Primary:
To characterize the safety and confirm tolerability of ABBV-101

Secondary:
To evaluate the pharmacokinetics (PK) following oral dose administration of ABBV-101
To evaluate the preliminary efficacy of ABBV-101 in specified subsets of participants with R/R B-cell NHL as defined by the disease-specific response criteria

Protocol Number: 012321
Phase: Phase I
Applicable Disease Sites: Non-Hodgkin's Lymphoma
Drugs Involved: ABBV-101
Principal Investigator: Joanna Rhodes
Scope: National
Therapies Involved: Chemotherapy single agent systemic
Participating Institutions:
  • Rutgers University
Inclusion & Exclusion Criteria

Please note that we have obtained the inclusion and exclusion criteria information from the National Institutes of Health’s clinical trials web site ClinicalTrials.gov. The listed criteria may not necessarily reflect recent amendments to the protocol and the current criteria.

For further information about clinical trials, please contact us at 732-235-7356.